SCHEMBL5688089

SCHEMBL5688089

Cc1ccc(CCc2ccc(OC(=O)N3CCC(COc4ccc(C(=O)O)cc4)CC3)cc2)nc1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.43
AOC3 Q16853 1/20 0.42
KCNH2 Q12809 2/20 0.39
HTR4 Q13639 1/20 0.39
SSTR5 P35346 1/20 0.39
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
LIPE Q05469 2/20 0.39
GPR119 Q8TDV5 3/20 0.38
CHEK2 O96017 1/20 0.38
NPY2R P49146 1/20 0.38
FAAH O00519 1/20 0.38
HDAC1 Q13547 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5687917 0.92 GRIN2B (0.44) GRIN2BKCNH2SSTR5CYP4F2CYP4A11
SCHEMBL5931578 0.91 GRIN2B (0.43) GRIN2BAOC3CYP4F2CYP4A11LIPE
SCHEMBL5931494 0.88 LIPE (0.51) GRIN2BAOC3CYP4F2CYP4A11LIPE
SCHEMBL5687972 0.88 SRD5A2 (0.45) AOC3GPR119NPC1RAB9A
SCHEMBL5690284 0.86 GRIN2B (0.43) GRIN2BKCNH2HTR4SSTR5CYP4F2
SCHEMBL5689825 0.85 KCNH2 (0.42) GRIN2BKCNH2HTR4SSTR5LIPE
SCHEMBL5931566 0.85 LIPE (0.46) GRIN2BAOC3CYP4F2CYP4A11LIPE
SCHEMBL5690554 0.83 GRIN2B (0.44) GRIN2BCYP4F2CYP4A11LIPEGPR119
SCHEMBL5715429 0.81 AOC3 (0.43) AOC3
SCHEMBL5688252 0.81 GRIN2B (0.44) GRIN2BAOC3CYP4F2CYP4A11LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
CN-1805951-A Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-19 CN claimed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160851-A1 Substituted piperidine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
CN-1805951-A Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase NOVO NORDISK AS (DK) 2006-07-19 CN disclosed
EP-1636207-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111032-A1 SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160851-A1 Substituted piperidine carbamates LIPE, PNLIP, LIPC GRIN2B 2588/4885AOC3 1480/4885KCNH2 2290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.